JP2013534527A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534527A5
JP2013534527A5 JP2013516909A JP2013516909A JP2013534527A5 JP 2013534527 A5 JP2013534527 A5 JP 2013534527A5 JP 2013516909 A JP2013516909 A JP 2013516909A JP 2013516909 A JP2013516909 A JP 2013516909A JP 2013534527 A5 JP2013534527 A5 JP 2013534527A5
Authority
JP
Japan
Prior art keywords
panthenol
use according
pharmaceutical composition
contact lens
dry weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013516909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534527A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2011/000827 external-priority patent/WO2012000055A1/en
Publication of JP2013534527A publication Critical patent/JP2013534527A/ja
Publication of JP2013534527A5 publication Critical patent/JP2013534527A5/ja
Pending legal-status Critical Current

Links

JP2013516909A 2010-07-02 2011-07-01 コンタクトレンズ乳頭結膜炎及びアレルギー性眼疾患の予防及び処置のための組成物 Pending JP2013534527A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010902954 2010-07-02
AU2010902954A AU2010902954A0 (en) 2010-07-02 Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
PCT/AU2011/000827 WO2012000055A1 (en) 2010-07-02 2011-07-01 Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease

Publications (2)

Publication Number Publication Date
JP2013534527A JP2013534527A (ja) 2013-09-05
JP2013534527A5 true JP2013534527A5 (enExample) 2014-08-21

Family

ID=45401233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013516909A Pending JP2013534527A (ja) 2010-07-02 2011-07-01 コンタクトレンズ乳頭結膜炎及びアレルギー性眼疾患の予防及び処置のための組成物

Country Status (9)

Country Link
US (2) US9161923B2 (enExample)
EP (1) EP2588096A4 (enExample)
JP (1) JP2013534527A (enExample)
CN (1) CN103037858A (enExample)
AU (1) AU2011274245B2 (enExample)
CA (1) CA2803935A1 (enExample)
SG (1) SG186782A1 (enExample)
TW (1) TW201206418A (enExample)
WO (1) WO2012000055A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513305B2 (en) 2007-05-14 2013-08-20 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
US9161923B2 (en) * 2010-07-02 2015-10-20 Brien Holden Vision Institute Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
AR089518A1 (es) * 2012-12-27 2014-08-27 Vega Villavicencio Parsival Costra artificial porosa semipermeable
EP2898888B8 (en) * 2014-01-22 2019-06-12 VISUfarma B.V. Composition comprising iota-carrageenan against viral Conjunctivitis
AU2014403039B2 (en) * 2014-08-08 2020-04-09 Shagnhai Hightide Biopharmaceutical, Ltd. Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
ES2827426T3 (es) * 2015-03-26 2021-05-21 Dmg Italia Srl Composición oftálmica para la protección corneal
EP3496516B1 (en) 2017-12-11 2020-02-19 Ion Beam Applications S.A. Superconductor cyclotron regenerator
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3827818A1 (en) * 2019-11-26 2021-06-02 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic composition
WO2025253406A1 (en) * 2024-06-05 2025-12-11 Sentiss Pharma Private Limited Dexpanthenol gel forming solution and method of preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211238B1 (en) * 1998-10-27 2001-04-03 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
JP2004521682A (ja) * 2001-01-09 2004-07-22 ルーイ・ヨハン・ワヘナール 眼を治療および／またはケアする方法と組成物
TW586945B (en) * 2001-01-12 2004-05-11 Novartis Ag Lens care product containing dexpanthenol
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
US20050220742A1 (en) 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
US20070243275A1 (en) 2006-04-13 2007-10-18 Gilbard Jeffrey P Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
WO2009094466A2 (en) * 2008-01-22 2009-07-30 University Of Florida Research Foundation, Inc. Contact lenses for extended release of bioactive agents containing diffusion attenuators
US20100087550A1 (en) * 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
NL2002214C2 (en) * 2008-11-17 2010-05-18 Louis Johan Wagenaar Contact lens care solution.
CA2760591C (en) 2009-05-01 2018-01-02 Advanced Vision Research, Inc. Cleanser compositions and methods for using the same
IT1393712B1 (it) 2009-05-13 2012-05-08 Bruschettini Srl Composizioni oftalmiche per la riepitelizzazione, la cicatrizzazione, e la disinfezione dei tessuti oculari
US9161923B2 (en) * 2010-07-02 2015-10-20 Brien Holden Vision Institute Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease

Similar Documents

Publication Publication Date Title
JP2016027060A5 (enExample)
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
JP2012533517A5 (enExample)
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
NZ704247A (en) Compositions and treatment for eye diseases and disorders
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
JP2010222367A5 (enExample)
JP2015057451A5 (enExample)
BR112015019039A2 (pt) antagonistas de integrina fluorados
AR092860A1 (es) Formulacion oftalmica y metodo para mejorar la presbicia
MX2016009063A (es) Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2014125426A (ru) Защитное средство для роговицы и конъюнктивы или супрессивное средство при кератоконъюнктивальном нарушении
JP2016531949A5 (enExample)
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
JP2013518051A5 (enExample)
JP2020531511A5 (enExample)
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
RU2018102746A (ru) Офтальмологическая фармацевтическая композиция
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
JP2016538288A5 (enExample)
MX381932B (es) Composicion intranasal que comprende betahistina.